Palvella Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Accounts Receivable of -$387.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-03-31
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$29.00K.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $0.00.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-06-30 was $0.00.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-03-31 was -$358.00K.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$387.00K.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$5.31M, a 302.25% decline from fiscal 2022.
- Palvella Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $2.62M, a 44.73% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$29.00K derived: sum of 2 quarters · filed 2026-03-31 | -$29.00K derived: sum of 3 quarters · filed 2026-03-31 | -$387.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | -$358.00K 10-Q · filed 2025-11-12 | -$358.00K derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$358.00K 10-Q · filed 2025-08-14 | -$358.00K derived: sum of 3 quarters · filed 2026-03-31 | -$358.00K derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-03-31 | -$358.00K 10-Q · filed 2025-05-15 | -$358.00K derived: sum of 2 quarters · filed 2026-03-31 | -$358.00K derived: sum of 3 quarters · filed 2026-03-31 | -$358.00K derived: sum of 4 quarters · filed 2026-03-31 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $0.00 10-K · filed 2026-03-31 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$5.31M 10-K · filed 2024-03-29 | ||||
| 2022-12-31 | $2.62M 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | $1.81M 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | -$5.34M 10-K · filed 2022-03-02 | ||||
| 2019-12-31 | $4.05M 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | -$12.51M 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | $12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$32.02M derived: sum of 2 quarters · filed 2019-03-18 | $14.49M derived: sum of 3 quarters · filed 2019-03-18 | $14.47M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$44.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $2.36M derived: sum of 2 quarters · filed 2017-11-13 | $2.34M 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | $46.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $46.49M 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | -$19.33K 10-Q · filed 2017-05-15 | ||||
| 2016-12-31 | $59.00K 10-K · filed 2018-03-15 | $58.65K 10-K · filed 2017-03-30 | |||
| 2016-03-31 | $68.87K 10-Q · filed 2017-05-15 | ||||
| 2015-09-30 | $17.33K 10-Q · filed 2016-11-10 | ||||
| 2014-12-31 | $9.03K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | -$396.83K derived: sum of 2 quarters · filed 2016-03-23 | $14.29K derived: sum of 3 quarters · filed 2016-03-23 | -$465.38K 10-K · filed 2016-03-23 | |
| 2014-09-30 | -$405.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $5.26K derived: sum of 2 quarters · filed 2015-11-13 | -$474.42K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | $411.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$68.55K 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | -$479.68K 10-Q · filed 2015-05-14 | ||||
| 2013-12-31 | $337.48K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |